Positive News SentimentPositive NewsNASDAQ:OGI Organigram (OGI) Stock Price, News & Analysis $1.40 -0.07 (-4.76%) Closing price 04:00 PM EasternExtended Trading$1.39 -0.01 (-0.71%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Organigram Stock (NASDAQ:OGI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organigram alerts:Sign Up Key Stats Today's Range$1.39▼$1.4850-Day Range$0.88▼$1.4752-Week Range$0.85▼$2.08Volume855,472 shsAverage Volume658,108 shsMarket Capitalization$187.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewOrganigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Read More… Organigram Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreOGI MarketRank™: Organigram scored higher than 13% of companies evaluated by MarketBeat, and ranked 892nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Organigram.Read more about Organigram's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Organigram are expected to grow in the coming year, from ($0.19) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organigram is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organigram is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganigram has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Organigram's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.74% of the float of Organigram has been sold short.Short Interest Ratio / Days to CoverOrganigram has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Organigram has recently decreased by 0.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganigram does not currently pay a dividend.Dividend GrowthOrganigram does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.74% of the float of Organigram has been sold short.Short Interest Ratio / Days to CoverOrganigram has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Organigram has recently decreased by 0.81%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment1.71 News SentimentOrganigram has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Organigram this week, compared to 1 article on an average week.Search Interest3 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Organigram to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organigram insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.09% of the stock of Organigram is held by insiders.Percentage Held by InstitutionsOnly 34.63% of the stock of Organigram is held by institutions.Read more about Organigram's insider trading history. Receive OGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter. Email Address OGI Stock News HeadlinesEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14, 2025 | uk.investing.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 13, 2025 | Brownstone Research (Ad)Organigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comSee More Headlines OGI Stock Analysis - Frequently Asked Questions How have OGI shares performed this year? Organigram's stock was trading at $1.61 at the beginning of the year. Since then, OGI stock has decreased by 13.0% and is now trading at $1.40. View the best growth stocks for 2025 here. How were Organigram's earnings last quarter? Organigram Holdings Inc. (NASDAQ:OGI) posted its earnings results on Tuesday, February, 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.02. Organigram had a negative trailing twelve-month return on equity of 8.59% and a negative net margin of 31.69%. Read the conference call transcript. When did Organigram's stock split? Shares of Organigram reverse split on the morning of Friday, July 7th 2023. The 1-4 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Organigram's major shareholders? Top institutional investors of Organigram include Wealth Enhancement Advisory Services LLC (0.02%). How do I buy shares of Organigram? Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organigram own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include i3 Verticals (IIIV), Ford Motor (F), Lucid Group (LCID), Trade Desk (TTD), Finance of America Companies (FOA), NVIDIA (NVDA) and Company Calendar Last Earnings2/11/2025Today6/13/2025Next Earnings (Estimated)8/12/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OGI CIK1620737 Webwww.organigram.ca Phone(844) 644-4726FaxN/AEmployees860Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.10 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.39 million Net Margins-31.69% Pretax Margin-31.53% Return on Equity-8.59% Return on Assets-6.54% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio1.85 Sales & Book Value Annual Sales$194.09 million Price / Sales0.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.77Miscellaneous Outstanding Shares133,884,000Free Float126,103,000Market Cap$189.45 million OptionableOptionable Beta1.37 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:OGI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.